PFE250110C27000
- 0.09
- -0.18-66.67%
Pfizer Newsroom
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Pfizer Is Maintained at Neutral by UBS
Pfizer Analyst Ratings
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
UBS Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $29
Pfizer Price Target Lowered to $29 From $31 at UBS
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
The FDA states that GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) RSV vaccines must include warnings about the rare risk of paralysis.
The FDA stated that a vaccine produced by GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) must include a warning about the potential increased risk of a rare neurological side effect.
Truist Financial Sticks to Its Buy Rating for Pfizer (PFE)
Pfizer Options Spot-On: On January 7th, 183.88K Contracts Were Traded, With 3.21 Million Open Interest
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
FDA Requires GSK and Pfizer Vaccines to Carry Rare Side Effect Warnings
GSK, Pfizer RSV Shots to Warn About Rare Neurological Disorder
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Express News | Pfizer Executives Descend on Donald Trump’s Mar-a-Lago for Planning Meeting - FT
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
PostEra Annonce L'extension À 610 Millions USD De Sa Collaboration Avec Pfizer Dans La Découverte De Médicaments Optimisée Par L'IA